Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement

Common Size IS
Op Efficiency
Credit Analysis

Inhibikase Therapeutics, Inc.

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
  Older >>
In millions, except per share itemsJun-30-23Mar-31-23Dec-31-22Sep-30-22Jun-30-22Mar-31-22Dec-31-21Sep-30-21
   10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q
Revenue:          
Total revenue  0.30.10.10.10.41.73.13.3
            Total revenue growth  -34.3%-91.8%-96.0%-98.1%-87.1%-5.2%343.9% 
Revenue from Contract with Customer, Product and Service [Extensible List]          
Costs and expenses:          
Research and development  13.411.912.012.412.59.66.53.2
Selling, general and administrative  6.66.56.26.56.65.03.31.6
    Total costs and expenses  20.018.318.318.919.218.517.914.2
    Loss from operations  -19.8-18.2-18.1-18.8-18.8-16.5-14.3-9.5
            Operating margin  -7850.0%-12825.3%-14686.2%-30468.6%-4907.0%-951.4%-461.5%-292.1%
Interest income (expense)  0.70.2   0.00.0 
    Net loss  -19.0-17.9-18.1-18.8-18.8-16.8-14.8-11.0
   
Other comprehensive income, net of tax          
Unrealized loss on marketable securities  -0.2       
    Comprehensive Loss  -5.9   -4.6   
   
Net loss per share - basic  ($1.62)($1.61)($1.63)($1.66)($1.66)($0.78)($0.86)($0.81)
Net loss per share - diluted  ($1.62)($1.61)($1.63)($1.66)($1.66)($0.56)($0.38)($0.18)
   
Weighted average number of common share - basic  20.820.520.018.218.220.216.413.9
Weighted average number of common share - diluted  20.820.520.018.218.217.110.86.3

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy